Terumo (OTCMKTS:TRUMY) Sets New 12-Month Low – Should You Sell?

Terumo Corp. (OTCMKTS:TRUMY) shares reached a new 52-week low on Tuesday . The company traded as low as $12.40 and last traded at $12.52, with a volume of 3329 shares trading hands. The stock had previously closed at $13.34.

Terumo Trading Down 14.3%

The company has a market capitalization of $18.53 billion, a PE ratio of 21.66 and a beta of 0.74. The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07. The business’s 50-day simple moving average is $14.13 and its two-hundred day simple moving average is $15.87.

Terumo (OTCMKTS:TRUMY) last issued its quarterly earnings results on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Terumo had a net margin of 11.74% and a return on equity of 9.13%. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.82 billion.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.